Hospital
Clinch Valley Medical Center INC.
Clinch Valley Medical Center INC. was paid $26.28M by Medicaid between Jan 2018 and Dec 2024, across 338 billing codes. Its largest line is 99284, emergency room visit (serious) — 12% of everything it billed.
33Billing provider infoCLINCH VALLEY MEDICAL CENTER INC.
RICHLANDS, VA 24641
RICHLANDS, VA 24641
33aNPI1871534297assigned 06/09/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$26.28M
24GClaims877,299
24DCodes billed338
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#27 of 80
Median peer was paid$14.69M
This provider vs. median1.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 110,496 | $2.23M | |
| 2019 | 137,432 | $3.63M | |
| 2020 | 115,910 | $3.51M | |
| 2021 | 132,099 | $3.86M | |
| 2022 | 129,718 | $4.06M | |
| 2023 | 139,822 | $4.91M | |
| 2024incomplete | 111,822 | $4.07M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 22,666 | 19,397 | $3.27M |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.1% | 9,471 | 7,251 | $2.13M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.6% | 14,778 | 12,881 | $2.00M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.1% | 9,458 | 7,794 | $1.33M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.0% | 5,517 | 4,931 | $1.04M |
| 41899 | Unlisted procedure, dentoalveolar structures | 3.7% | 590 | 553 | $960K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 3.3% | 1,577 | 1,395 | $864K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.1% | 2,961 | 2,695 | $821K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.9% | 1,950 | 1,755 | $771K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.7% | 7,007 | 4,806 | $699K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 3,735 | 3,266 | $640K |
| 11043 | 2.4% | 2,725 | 1,437 | $629K |
326 more codes
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 2.2% | 1,445 | $570K |
| G0378 | Hospital observation service, per hour | 1.9% | 8,087 | $511K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.8% | 3,498 | $476K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.6% | 2,046 | $426K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.6% | 3,171 | $411K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 2,142 | $401K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 3,324 | $398K |
| 80053 | Comprehensive metabolic panel | 1.3% | 47,108 | $346K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 9,710 | $282K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,819 | $241K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,252 | $214K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 51,055 | $212K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,962 | $201K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,728 | $190K |
| 71250 | <1% | 2,472 | $173K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,674 | $170K |
| 93017 | <1% | 1,884 | $159K | |
| 97032 | <1% | 3,474 | $152K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,667 | $138K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 19,884 | $136K |
| 96367 | <1% | 2,662 | $134K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,496 | $132K |
| 29581 | <1% | 1,083 | $123K | |
| 80061 | Lipid panel | <1% | 13,345 | $123K |
| 95886 | <1% | 589 | $118K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,997 | $109K |
| 74178 | <1% | 574 | $109K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,623 | $108K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 604 | $104K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 17,666 | $103K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,436 | $97K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,882 | $96K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 4,782 | $95K |
| 81001 | <1% | 21,467 | $92K | |
| 80306 | <1% | 6,617 | $88K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,740 | $87K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,506 | $87K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,044 | $87K |
| 93970 | <1% | 831 | $85K | |
| 86803 | <1% | 1,889 | $84K | |
| 86003 | <1% | 1,911 | $78K | |
| 82607 | <1% | 4,021 | $77K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,195 | $73K |
| 82728 | <1% | 4,843 | $73K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,605 | $72K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,942 | $70K |
| 97161 | <1% | 438 | $69K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12,535 | $67K |
| 87522 | Neg quan hep c or qual rna | <1% | 1,812 | $63K |
| 80076 | <1% | 2,453 | $61K | |
| 93971 | <1% | 725 | $60K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 795 | $59K |
| 36415 | Collection of venous blood by venipuncture | <1% | 44,888 | $59K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,371 | $58K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 89 | $57K |
| 84439 | <1% | 5,868 | $55K | |
| 76536 | <1% | 538 | $54K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,707 | $54K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,572 | $53K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 28 | $50K |
| 83880 | <1% | 4,890 | $49K | |
| 96523 | <1% | 783 | $48K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,571 | $45K |
| 87040 | <1% | 5,156 | $44K | |
| 83550 | <1% | 4,531 | $43K | |
| 83655 | <1% | 2,591 | $42K | |
| 73564 | <1% | 2,095 | $40K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 630 | $39K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,062 | $38K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,051 | $38K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 364 | $38K |
| 72110 | <1% | 1,313 | $38K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 374 | $35K |
| 87902 | <1% | 407 | $35K | |
| 87077 | <1% | 6,059 | $34K | |
| 84702 | <1% | 2,480 | $34K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 872 | $32K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,150 | $31K |
| 84145 | <1% | 5,023 | $31K | |
| 73630 | <1% | 1,733 | $31K | |
| 80074 | <1% | 1,478 | $28K | |
| 93880 | <1% | 389 | $27K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 96 | $26K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,363 | $26K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 43 | $25K |
| 73610 | <1% | 1,582 | $25K | |
| 82785 | <1% | 1,638 | $24K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,457 | $24K |
| 73030 | <1% | 1,224 | $23K | |
| 87186 | <1% | 5,838 | $22K | |
| 94726 | <1% | 539 | $22K | |
| 83540 | <1% | 4,637 | $22K | |
| 74018 | <1% | 868 | $21K | |
| 84484 | <1% | 11,235 | $21K | |
| 94375 | <1% | 557 | $20K | |
| 85379 | <1% | 4,758 | $20K | |
| 78227 | <1% | 69 | $20K | |
| 83735 | <1% | 10,827 | $19K | |
| 77080 | <1% | 341 | $19K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 456 | $18K |
| 80050 | General health panel | <1% | 43 | $17K |
| 94200 | <1% | 541 | $17K | |
| 72131 | <1% | 242 | $16K | |
| 73130 | <1% | 787 | $16K | |
| 85610 | <1% | 10,631 | $16K | |
| 82570 | <1% | 1,545 | $15K | |
| 87070 | <1% | 3,149 | $15K | |
| 85652 | <1% | 2,218 | $14K | |
| 84402 | <1% | 983 | $14K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 12,689 | $14K |
| 73110 | <1% | 742 | $14K | |
| 76642 | <1% | 104 | $12K | |
| 97162 | <1% | 554 | $12K | |
| 76641 | <1% | 91 | $12K | |
| 84403 | <1% | 921 | $12K | |
| 86038 | <1% | 558 | $11K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 28 | $11K |
| 83605 | <1% | 6,909 | $10K | |
| 94729 | <1% | 483 | $10K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,592 | $10K |
| 84550 | <1% | 734 | $10K | |
| 82043 | <1% | 2,483 | $10K | |
| 83690 | <1% | 7,857 | $10K | |
| 82962 | <1% | 10,917 | $10K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 57 | $10K |
| 82150 | <1% | 3,180 | $9K | |
| 82565 | <1% | 2,212 | $9K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,947 | $9K |
| 86738 | <1% | 1,240 | $9K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 13,078 | $9K |
| 84153 | <1% | 977 | $8K | |
| 90715 | <1% | 536 | $8K | |
| 84100 | <1% | 3,679 | $8K | |
| 82746 | <1% | 930 | $8K | |
| 86140 | <1% | 1,895 | $8K | |
| 84481 | <1% | 596 | $8K | |
| 80081 | <1% | 505 | $8K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 790 | $7K |
| 84703 | <1% | 3,793 | $7K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 7,252 | $7K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 662 | $7K |
| 88342 | <1% | 1,282 | $7K | |
| 83001 | <1% | 252 | $7K | |
| 96415 | <1% | 27 | $7K | |
| 82677 | <1% | 349 | $7K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 70 | $6K |
| 84436 | <1% | 220 | $6K | |
| 88304 | <1% | 573 | $6K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 7,302 | $6K |
| 87507 | <1% | 234 | $6K | |
| 87205 | <1% | 3,034 | $6K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 66 | $6K |
| 78451 | <1% | 36 | $6K | |
| 73502 | <1% | 348 | $6K | |
| 82784 | <1% | 479 | $6K | |
| 87631 | <1% | 216 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 790 | $6K |
| 76937 | <1% | 147 | $5K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 64 | $5K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 62 | $5K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,735 | $5K |
| 93225 | <1% | 139 | $5K | |
| 95911 | <1% | 195 | $5K | |
| 85027 | <1% | 379 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,940 | $5K |
| 82550 | <1% | 376 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,190 | $5K |
| 78226 | <1% | 13 | $5K | |
| J2704 | Injection, propofol, 10 mg | <1% | 7,606 | $5K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,078 | $4K |
| 85730 | <1% | 6,470 | $4K | |
| 96368 | <1% | 580 | $4K | |
| 81025 | <1% | 4,189 | $4K | |
| 81596 | <1% | 62 | $4K | |
| 10060 | <1% | 12 | $4K | |
| 87505 | <1% | 89 | $4K | |
| 86141 | <1% | 1,524 | $3K | |
| 86336 | <1% | 347 | $3K | |
| 82805 | <1% | 737 | $3K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 121 | $3K |
| 29125 | <1% | 18 | $3K | |
| 86850 | <1% | 900 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 358 | $3K |
| 76770 | <1% | 25 | $3K | |
| 82947 | <1% | 318 | $3K | |
| 82977 | <1% | 229 | $3K | |
| 29799 | <1% | 15 | $3K | |
| 87486 | <1% | 494 | $3K | |
| 87481 | <1% | 148 | $3K | |
| 86800 | <1% | 187 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,191 | $3K |
| 93226 | <1% | 139 | $3K | |
| 87150 | <1% | 346 | $3K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 241 | $3K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,286 | $3K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,423 | $2K |
| 86901 | <1% | 1,461 | $2K | |
| 93246 | <1% | 75 | $2K | |
| 87529 | <1% | 165 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,801 | $2K |
| 84146 | <1% | 45 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,100 | $2K |
| 86431 | <1% | 470 | $2K | |
| 87581 | <1% | 494 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,472 | $2K |
| 85014 | <1% | 256 | $2K | |
| 83615 | <1% | 244 | $2K | |
| 86900 | <1% | 1,470 | $2K | |
| 88312 | <1% | 556 | $2K | |
| 72050 | <1% | 46 | $2K | |
| 84681 | <1% | 38 | $2K | |
| J3490 | Unclassified drugs | <1% | 270 | $2K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 70 | $2K |
| 96376 | <1% | 2,683 | $2K | |
| 80171 | <1% | 180 | $2K | |
| 85018 | <1% | 289 | $2K | |
| 86317 | <1% | 67 | $1K | |
| 76870 | <1% | 14 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 547 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,300 | $1K |
| 93922 | <1% | 15 | $1K | |
| 95912 | <1% | 14 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 108 | $1K |
| 74246 | <1% | 14 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,248 | $1K |
| 82140 | <1% | 392 | $1K | |
| 83516 | <1% | 32 | $1K | |
| 87340 | <1% | 107 | $1K | |
| 77066 | Tomosynthesis, mammo | <1% | 64 | $1K |
| 86592 | <1% | 122 | $1K | |
| 83002 | <1% | 37 | $1K | |
| 86235 | <1% | 27 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 26 | $1K |
| 86677 | <1% | 124 | $1K | |
| 86225 | <1% | 71 | $985.82 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,908 | $912.50 |
| 36600 | <1% | 622 | $897.23 | |
| 86704 | <1% | 65 | $867.31 | |
| 73080 | <1% | 73 | $849.97 | |
| 86200 | <1% | 148 | $769.33 | |
| 87338 | <1% | 34 | $737.87 | |
| J2805 | Injection, sincalide, 5 micrograms | <1% | 13 | $721.83 |
| 87506 | <1% | 17 | $720.22 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 56 | $600.74 |
| 97035 | <1% | 33 | $592.05 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,950 | $571.80 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,763 | $529.74 |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 248 | $488.59 |
| 0002A | <1% | 13 | $484.24 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 3,014 | $480.87 |
| 74248 | <1% | 12 | $458.31 | |
| 0001A | <1% | 29 | $451.70 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 964 | $448.33 |
| 73590 | <1% | 58 | $448.22 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,621 | $440.22 |
| S9470 | Nutritional counseling, dietitian visit | <1% | 104 | $423.04 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 930 | $415.04 |
| 83010 | <1% | 70 | $409.84 | |
| 82105 | <1% | 30 | $403.71 | |
| 84450 | <1% | 114 | $399.14 | |
| 86708 | <1% | 16 | $384.19 | |
| 84460 | <1% | 126 | $363.07 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,890 | $358.70 |
| G0379 | Direct admission of patient for hospital observation care | <1% | 62 | $355.46 |
| 86665 | <1% | 27 | $348.99 | |
| 86376 | <1% | 37 | $339.18 | |
| 83525 | <1% | 31 | $332.74 | |
| 82172 | <1% | 37 | $312.10 | |
| 95913 | <1% | 46 | $311.88 | |
| 82248 | <1% | 44 | $306.38 | |
| 86231 | <1% | 55 | $291.35 | |
| 84478 | <1% | 66 | $282.42 | |
| 87177 | <1% | 41 | $280.82 | |
| 82652 | <1% | 25 | $280.03 | |
| 87807 | <1% | 663 | $264.64 | |
| 99152 | <1% | 249 | $259.10 | |
| 88300 | <1% | 108 | $255.40 | |
| 86364 | <1% | 76 | $254.64 | |
| 86258 | <1% | 76 | $254.64 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 470 | $253.38 |
| 36591 | <1% | 13 | $250.31 | |
| 87329 | <1% | 41 | $246.66 | |
| 82247 | <1% | 76 | $188.78 | |
| 90686 | <1% | 14 | $176.81 | |
| 82465 | <1% | 38 | $172.04 | |
| 87045 | <1% | 29 | $170.49 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 671 | $166.80 |
| A9270 | Non-covered item or service | <1% | 4,292 | $149.35 |
| 96417 | <1% | 223 | $130.86 | |
| 88311 | <1% | 12 | $125.06 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,537 | $101.69 |
| 81003 | <1% | 34 | $98.87 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 812 | $89.43 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 205 | $77.57 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 596 | $72.97 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 689 | $59.83 |
| J1815 | Injection, insulin, per 5 units | <1% | 369 | $53.84 |
| 87427 | <1% | 15 | $45.22 | |
| 82272 | <1% | 63 | $43.66 | |
| 84156 | <1% | 20 | $36.71 | |
| 86769 | <1% | 14 | $35.59 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 307 | $32.54 |
| 86308 | <1% | 12 | $31.56 | |
| 87081 | <1% | 17 | $28.14 | |
| 84520 | <1% | 30 | $26.43 | |
| 85049 | <1% | 17 | $21.22 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 142 | $18.42 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 539 | $17.75 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 44 | $17.48 |
| 85045 | <1% | 12 | $14.52 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 88 | $14.24 |
| 99153 | Mod sedat endo service >5yrs | <1% | 12 | $11.83 |
| C1769 | Guide wire | <1% | 196 | $11.74 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 133 | $10.22 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 295 | $9.43 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 14 | $9.05 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 222 | $4.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 74 | $2.42 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 13 | $2.16 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 35 | $1.35 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 163 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 93 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 90 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 16 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 91 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.